QLT (QLTI) Said The FDA To Review Aczone labeling supplement
More News related to QLTI
- QLT announces Toronto Stock Exchange approval of share repurchase program
- QLT Inc. (QLTI) reports Q3 EPS of $0.04
- QLT Inc. (QLTI) Reports Q3 Adj-Loss of $0.08; to Buyback Up to 5% of Shares
- QLT Announces Share Repurchase Program
- QLT Inc. (QLTI) Announces Simplified Novartis Pharma (NVS) Relationship; Will Have Exclusive Visudyne Rights
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
QLT Inc. (NASDAQ: QLTI) said the FDA has accepted for filing and review QLT USA, Inc.'s labeling supplement for Aczone to request the removal of the glucose-6-phosphate dehydrogenase screening and blood monitoring requirements from its current label. A decision by the FDA on the label revision is expected by the end of March 2008.
Related Categories
FDAStocks Mentioned
+0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
